Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design

Autor: Jean Bourbeau, François Maltais, Thierry Troosters, Damijan Erzen, Nancy Leidy, Dorothy De Sousa, Lawrence Korducki, Alan Hamilton

Publikováno v: BMJ Open, Vol 6, Iss 4 (2016)

Introduction Chronic obstructive pulmonary disease (COPD) is associated with exercise limitation and physical inactivity, which are believed to have significant long-term negative health consequences for patients. While a number of COPD treatments an

Externí odkaz: https://doaj.org/article/7833bf4b76bd4d6f88bbaadb6a5aa1e4

Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease

Autor: Kim L. Lavoie, Damijan Erzen, Jean Bourbeau, François Maltais, Lawrence Korducki, Alan Hamilton, Thierry Troosters, Maria Sedeno, Wim Janssens, Nancy Kline Leidy, Judith Garcia-Aymerich, Dorothy De Sousa

Publikováno v: American journal of respiratory and critical care medicine. 198(8)

Bronchodilation and exercise training (ExT) improve exercise tolerance in patients with chronic obstructive pulmonary disease (COPD); however, behavior modification is required to impact daily physical activity (PA).To assess whether tiotropium/oloda

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7209d561913570306509e142e4455382
https://pubmed.ncbi.nlm.nih.gov/29758168

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

Autor: Ulrich Bothner, Lorcan McGarvey, Gary T. Ferguson, Alan Hamilton, Sheldon Magder, Kay Tetzlaff, Claus Vogelmeier, Dennis E. Niewoehner, Paul Sachs, Andrea Koch, Lawrence Korducki

Publikováno v: COPD
McGarvey, L, Niewoehner, D, Magder, S, Sachs, P, Tetzlaff, K, Hamilton, A, Korducki, L, Bothner, U, Vogelmeier, C, Koch, A & Ferguson, G T 2015, ' One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis ', COPD: Journal of Chronic Obstructive Pulmonary Disease, vol. 12, no. 5, pp. 484-493 . https://doi.org/10.3109/15412555.2014.991864

The novel long-acting β2-agonist olodaterol demonstrated an acceptable safety profile in short-term phase II clinical studies. This analysis of four randomized, double-blind, placebo-controlled, parallel-group, phase III studies (1222.11, NCT0078221

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::895fc794cc36736b78c3ea79ab11965e
http://europepmc.org/articles/PMC4778540

Effect of 8 and 12 weeks' once-daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with COPD

Autor: D De Sousa, François Maltais, Lawrence Korducki, Thierry Troosters, Nancy Kline Leidy, Wim Janssens, Kim L. Lavoie, Alan Hamilton, Jean Bourbeau, Damijan Erzen

Publikováno v: 5.1 Airway Pharmacology and Treatment.

Introduction: Physical deconditioning is common in patients with COPD, limiting exercise tolerance. Aim: PHYSACTO ® (NCT02085161) tested the effects of bronchodilators alone or with exercise training (ExT), combined with a standardised physical acti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0fd9c5d652152983b3670dba5e1d117
https://doi.org/10.1183/13993003.congress-2016.pa976

Analysis Of The Efficacy And Safety Of The Fixed-Dose Combination Of Tiotropium + Olodaterol In Patients With COPD By Initial Disease Severity

Autor: Lars Grönke, Gary T. Ferguson, Lawrence Korducki, Valeria C. Amatto, Roger Abrahams, M Haensel, Roland Buhl, Stephanie Korn

Publikováno v: Pneumologie. 70

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7c9e851d755e1b12f5299f465f49bfe1
https://doi.org/10.1055/s-0036-1572055